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Background: Malaria remains a burden for pregnant women and the under 5. Intermittent preventive treatment of
pregnant women (IPTp) for malaria with sulfadoxine – pyrimethamine (SP) has since replaced prophylaxis and
legislation has been reinforced in the area of insecticide treated mosquito nets (ITNs) in Cameroon. Clinical malaria
despite all these measures remains a problem. We compared the socio-obstetrical characteristics of women who
developed clinical malaria and those who did not though in the same regimen.
Methods: A 5 – year nested cohort study (2007 – 2011 inclusive) at the tertiary level hospitals in Yaounde.
Pregnant women who willingly accepted to participate in the study were enrolled at booking and three doses of
SP were administered between 18 – 20 weeks of gestation, between 26–28 weeks and between 32 – 34 weeks.
Those who developed clinical malaria were considered as cases and were compared for socio – obstetrical
characteristics with those who did not. Venous blood was drawn from the women in both arms for parasite density
estimation and identification and all the clinical cases were treated conventionally.
Results: Each arm had 166 cases and many women who developed clinical malaria were between 15 and 19 years
(OR 5.5, 95% CI 3.9 – 5.3, p < 0.001). They were of low gravidity (OR 6.5, 95% CI 3.8 – 11.3, p < 0.001) as well as low
parity (OR 4.6, 95% CI 2.7 – 7.9, p < 0.001). The cases were single women (OR 4.58, 95% CI 2.54 – 8.26, p < 0.001) and
had attained only primary level of education (OR 4.6, 95% CI 2.8 – 7.9, p < 0.001). Gestational ages were between
20 to 30 weeks during clinical malaria (OR 6.8, 95% CI 4.1 – 11.7, p < 0.001). The time between the first and second
dose of SP was longer than ten weeks in the cases (OR 5.5, 95% CI 3.2 – 9.3, p < 0.001) and parasite density was
higher also among the cases (OR 6.9, 95% CI 5.9 – 12.1, p < 0.001).
Conclusion: Long spacing between the first and second dose of SP seemed to be responsible for clinical malaria in
the cases.
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Malaria in pregnancy (MiP) generates public health con-
cerns across the globe, particularly in malaria – endemic
settings and results in adverse outcomes both for the
woman and foetus [1-5]. Malaria in Cameroon, as it is in
other resource restricted countries has a negative impact
on the health of children and pregnant women, espe-
cially the primigravidae. Indeed, higher susceptibility to
malaria is noted among pregnant women probably due
to a decrease in their immune responses [6-8].
Management of malaria in pregnancy now combines
multiple approaches [9-11]. Some of these approaches
include intermittent preventive treatment of pregnant
women (IPTp) for malaria using a bimolecular formula-
tion of sulphadoxine – pyrimethamine combined with
sleeping in insecticide treated nets (ITNs) [12-15]. These
two approaches have been recommended for pregnant
women living in endemic areas and are still in use today
[16-18]. Effort is being made to scale – up these proce-
dures in Cameroon.
A consensus that favored the use of these approaches
was arrived at by the health authorities in Cameroon in
the year 2004 and is still in force [19]. Thus, pregnant
women are health-provider administered three doses of
SP (three tablets per dose) during the course of preg-
nancy. The first dose is usually administered between
the 16th and the 20th week or when the first fetal move-
ments (quickening) are felt. The second dose is adminis-
tered at least thirty days after the first. This interval is
not fixed but is usually between the 26th and the 28th
week of gestation and the last dose is between the 33rd
and the 34th week. Alongside IPTp, ITNs are distributed
freely to pregnant women from booking visits.
Though these procedures form a common package in
our antenatal care delivery, clinical cases of malaria
among pregnant women constitute about 30 to 40% of
our daily hospital admissions. The aim of this study was
to analyze the socio – obstetrical characteristics of cases
of clinical malaria and match them against women who
did not develop malaria in the same cohort.
Methods
For a period of five years (2007–2011 inclusive), a cohort
of 2525 pregnant women was followed-up from booking
to delivery in the outpatient units of three tertiary level
hospitals in Yaounde from where clinical cases of mal-
aria and none malaria cases were recruited. These hospi-
tals are all affiliated to the University of Yaounde I,
Faculty of Medicine and Biomedical Sciences (FMBS).
Women who were HIV infected and those who re-
fused to participate freely in the study were not en-
rolled. We also eliminated women with fever producing
pathologies such as acute pyelonephritis and other con-
firmed infections.Enrollment was between 16 and 20 weeks of gestation.
Ethical clearance N°243/CNE/SE/2006 was obtained from
the National Ethics Committee and written or verbal
consents were also obtained. The women had complete
clinical and paraclinical evaluations. Viable pregnancies
were confirmed with ultrasound. Three doses of SP were
health – provider administered based on updated WHO
policy recommendations. They were provided freely with
ITNs on enrollment and phone calls and or home visits
were carried out to ensure that the women were sleeping
under ITNs.
The women were evaluated every visit for evidence of
clinical malaria and those who were symptomatic for
clinical malaria were hospitalized and treated. Clinical
malaria was defined as an acute onset of fever, chills, an-
orexia, vomiting, muscular or articular pain or both and
headache, all these in the absence of any concomitant
pathologies such as urinary tract infection and pneumo-
nia. Parasite densities were estimated during symptoms
and compared with parasite densities from women who
did not have symptoms.
Sample size estimation
Previous studies indicated that about 30% of pregnant
women develop clinical malaria in Cameroon [20].
This infers, therefore, that the proportion of pregnant
women unexposed to IPTp and ITNs who are expected
to exhibit the outcome of interest (Po), that is, clin-
ical malaria is 0.3. We hypothesized that this propor-
tion would be reduced by 50% (P1 = 0.15) if pregnant
women were exposed to both methods and that no par-
ticipant would leave the study (f = 0). Based on these
assumptions, the required sample size for the cohort
study was 133 rounded up for convenience to 166,
N ¼ 11 − f
2  zα þ zβð Þ2  p  1 ‐ pð Þ
p0 − p1ð Þ2
 
[21].Selection of exposed and unexposed cases
Cases of clinical malaria (exposed cases) and the rest of the
cohort followed up were enrolled in the same period. For
each case of clinical malaria enrolled, a pregnant woman
recruited at the antenatal clinic who did not present with
symptomatic malaria and who was matched for parity and
gestational age was enrolled for comparism.Quantification of serum plasmodium density
Two weeks after the first dose of SP, thumb prick blood
samples were collected for quantification of serum plas-
modium densities which served as baseline values for the
two groups. We assumed that these D1 parasite densities
values would be low after treatment. Subsequently, smears
were prepared from the women with clinical malaria as
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pared with D1 values.
Microscopy
Thick blood smears each measuring about 6 μL were
stained with 10% Giemsa and examined under the ×100
oil immersion objective lens using Olympus CH30 micro-
scope by two blinded laboratory scientists. Parasite dens-
ities were calculated from these thick smears and the thin
smears served to differentiate Plasmodium species. The
number of asexual parasites was estimated against 200
leucocytes using an average leucocytes count of 8, 000/μL
as recommended [22]. A smear was considered negative
only after 200 high power fields were examined.
Estimation of parasite density
Parasite densities (parasite/μL of whole blood) were a ra-
tio of parasites to WBCs in the Giemsa – stained thick
smears. Parasites (Plasmodium specy) were counted
against 200 WBCs. Calculation was as follows:
= N° of parasites counted/WBC counted × WBC count/
μL of participants’s whole blood [23].
Treatment of clinical cases
Confirmed cases were hospitalized for treatment with
Quinine Sulphate at 25 mg/kg/24 hours. Three equi –
doses were administered daily but not exceeding 1.5 g/
24 hours irrespective of body weight or body mass index
(BMI). Administration was parenteral during the first
72 hours in combination with paracetamol at 60 mg/
24 hrs as adjuvant treatment. From the fourth day, both
drugs were administered orally maintaining the same
doses for a total duration of treatment of seven days.
Statistical analysis
Data were entered into spread sheets and analyzed using
EPI-Info™ version 3.5.1. Parasite densities were calcu-
lated based on the hypothesis that parasite densities dur-
ing clinical malaria (D2) were higher than the initial
densities (D1) which were considered as parasite dens-
ities before clinical malaria. We calculated odds ratios
(OR) and 95% confidence intervals (C1) for the various
variables we cross-tabulated that needed comparison be-
tween the exposed and unexposed cases. Kruskal-Wallis
test was used to estimate the P – values whereby smaller
P – values (less than 0.05) were considered statistically
significant.
Ethical considerations
Ethical clearance was obtained from the national Ethics
Committee and authorization was obtained from the hos-
pital administrations. Data collection did not require any
expenditure by the women enrolled and both handling
and analysis of data conformed to strict confidentiality.Results
A total of 2525 pregnant women were followed up dur-
ing the study period out of which 166 developed clinical
malaria. We selected 166 pregnant women from the
same cohort who did not develop clinical malaria and
compared their socio-demographic characteristics.
Socio-demographic characteristics
An equal number of clinical cases were matched against
those who did not have symptoms (166 vs 166). Greater
proportions of cases were between 15 and 19 years (OR
3.42, 95% CI 2.10 – 5.59) and were of low gravidity (OR
3.77, 95% CI 2.15 – 6.61) as well as low parity (OR 2.91,
95% CI 1.68 – 5.01). The cases were single mothers (OR
4.58, 95% CI 2.54 – 8.26) and educated only at primary
level (OR 3.69, 95% CI 1.58 – 4.58). Gestational ages at the
time of attacks were between 20 to 30 weeks in the cases
(OR 4.25, 95% CI 2.45 – 7.37). Time interval between the
first and second dose of SP was greater than ten weeks in
the cases (OR 5.43, 95% CI 3.04 – 9.71) (Tables 1 and 2).
Parasite densities
WBC ranged from 1,700 to 16,000 with a median of
9,300 cells/μL in clinical malaria cases and from 1,600 to
13,000 with a median of 6, 555 cells/μL in asymptomatic
cases. The geometric mean of the parasites, that is
SD, were 13, 234.5 and 7, 834.7 ring trophozoites/μL re-
spectively using the actual WBC count.
Discussion
Parasitic infections become more severe during preg-
nancy especially in low resource settings. Women be-
come more susceptible to Plasmodium falciparum (PF)
infection during pregnancy. The reason for this remains
unclear, but changes in cell-mediated immunity are
thought to be involved. Enhanced susceptibility to mal-
aria infection means that when a woman becomes preg-
nant, she is most likely to develop malaria especially due
to PF [24-28].
Clinical symptoms of malaria include fever, chills,
sweats, nausea and vomiting [29,30]. All these symptoms
were manifested by our patients. Fever occurs when
schizonts rupture and release pyrogenic substances. The
presence of these substances triggers the over produc-
tion of cytokins such as interleukin-1 (IL-1), Interlenkin-
6 (IL-6) and Tumor Necrosis Factor-alpha (TNF- alpha)
[31]. These cytokins act on the thermoregulatory center
of the hypothalamus, provoking a rise in the internal
body temperature leading to fever, chills, shivering,
nausea, headache and pain. These symptoms occur fol-
lowing rapid multiplication of the parasite and sequestra-
tion of infected RBCs and immune complexes along
capillary walls. At this stage, the parasite density is high.
We used these symptoms to define clinical malaria in






OR 95% CI P-value
Age
15-19 64 36 2.097 0.55-3.41 0.036
20-24 24 18 1.374 1.09-4.02 0.646
25-29 30 25 1.275 0.69-2.35 0.533
30-34 20 27 0.683 0.36-1.31 0.324
35-39 28 40 0.299 0.30-1.37 0.339
Level of education
Higher 16 21 0.704 0.32-1.52 0.489
Secondary 72 61 1.522 0.88-2.62 0.168
Primary 22 28 0.732 0.39-1.38 0.421
Marital status
Married 36 33 1.127 0.56-2.24 0.771
Single 74 77 0.881 0.50-1.56
Employment status
Employed 35 27 1.434 0.79-2.59 0.294
Unemployed 75 83 0.697 0.39-1.26
Parity
Primiparous 58 30 2.974 1.70-5.22
0.0002
Multiparous 52 80 0.336 0.10-0.59
Table 3 Parasite densities
Type of malaria Median WBC count Geometric mean
Clinical 9,300 cells/μL 13, 234.5 ring trophozoites/μL
Asymptomatic 6, 555 cells/μL 7, 834.7 ring trophozoites/μL
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ence in the median WBC counts and geometric mean
in the two groups (Table 3). This higher parasite density
during clinical malaria is responsible for the blockage






OR 95% IC p
(n = 116) (n = 166)
Maternal age (yrs)
15 - 19 68 34 5.5 3.2-9.3 0.000
Gravidity 1 - 2 66 28 6.5 3.8-11.3 0.000
Parity 1 - 2 61 32 4.6 2.7-7.9 0.000
Primary education 76 48 4.6 2.8-7.8 0.000
Gestational
age 20 – 30 wks
74 34 6.8 4.1-11.7 0.000
Gestational
age > 30 wks
3 7 0.6 0.2-2.4 0.688
Parasite density
change (%)
64 25 6.9 3.9 - 12.1 0.000
Time between
1st & 2nd dose
10 weeks 68 34 5.5 3.2-9.3 0.000likened to thrombotic crisis observed in sickle cell
disease (SSD).
The effect of P. falciparum malaria on pregnant women
has been assessed in many African countries [32-34]. All
the cases we had here were of P. falciparum but mixed -
species Plasmodium falciparum and Plasmodium ovale
malaria have been reported [35]. Results show that PF in-
fection puts both the mother and the fetus at risk. Data
from several studies show that there is a higher incidence
of anaemia. Anaemia commonly occurs in women in en-
demic countries and becomes more severe during malaria
infection. It results not only from erythrocyte destruction
by the parasite, but also from the binding of malaria anti-
gens to the surface of normal erythrocytes which are in
turn removed by phagocytosis or complement mediated
lyses. Evidence of an association between anaemia and
malaria rather than pregnancy-associated anaemia is dem-
onstrated by the fact that there is reduced prevalence of
anaemia among pregnant women receiving antimalarial
drugs for prophylaxis. Most studies show that the preva-
lence of malaria parasitaemia in endemic areas signifi-
cantly increases during pregnancy in comparison to the
same women before pregnancy and to their age-matched
non-pregnant women. This is mostly marked in primigra-
vid women, with an average 2-fold increase in prevalence
compared to multigravidae [36-39].
Among the one hundred and sixty six (166) women
who developed clinical malaria in this study despite IPTp
and ITNs, 64 (38.55%) were between 15 and 19 years and
58 (34.94%) were in their first deliveries as against 21.69%
and 18.07% respectively in asymptomatic cases. Both par-
ity and length of gestation have an impact on susceptibility
to malaria infection. The susceptibility to infection among
non-immune women is similar in all parities [40]. Many
arguments have been advanced to explain the increased
susceptibility of pregnant women to malaria. However, the
clinical manifestations depend on the degree of endem-
icity of infection in the local environment and the number
of weeks of gestation. These largely depend on the inten-
sity and stability of malaria transmission in the area [41].
Education plays a role as women who are not well ed-
ucated are most likely to live in disadvantageous neigh-
borhoods. A good number of women among the cases
were educated at primary school level only (45.73% ver-
sus 28.92%) and gestational age during clinical malaria
was between 20 – 30 weeks (45.58% versus 20.48%). The
level of education did not influence significantly malaria
morbidity among the cases and the controls after
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who had attained secondary level of education was simi-
lar (OR 1.18, 95% CI, 0.67 – 2.09), to those who had uni-
versity education [OR 1.06, 95% CI, 0.45 – 2.25]. One
would have expected to find many women within the
secondary level of education to have more episodes of
clinical malaria as with primary level. However, in a
country like ours where 40% of the population lives
below poverty level, our neighborhoods are shared by a
population mix where one finds the highly educated
alongside those who have not been to school.
Malaria has always been a major public health problem
in Yaounde, Cameroon where many cases of P. falciparum
malaria occur every day. The prevalence of vector trans-
mission varies from one micro-ecological area to another,
resulting in variable levels of transmission [36].
Most of our patients came from the periphery of
Yaounde, areas plagued with swampy waters. The bulk
of our patients received the second dose of SP at inter-
vals greater than ten weeks. This may be explained by
the fact that the second dose of SP was not administered
in a uniform manner by our health care providers. In
some of the sites, the second dose was administered be-
tween the 26th and the 28th week of gestation while in
some others; administration was between the 28th and
the 30th week of gestation. Be it as it may, the interval
between the first and the second dose was rather too
long allowing for the effects of the drugs to fade out ex-
posing the women to infection.
The number of cases with clinical malaria declined
with increasing gestational age. The prevalence of infec-
tion was higher in the first and second trimesters of
pregnancy and decreased progressively in the third tri-
mester until delivery as described in literature [25,26].
Malaria is among the early pregnancy complications
observed among pregnant adolescents in Yaounde [42].
Conclusion
We conclude that primiparity and long intervals be-
tween the first and second dose of SP are responsible for
acute bouts of clinical malaria observed among pregnant
women who sleep under ITNs in our environment. Young
age, low level of education and pregnancies in the first half
of gestation also contribute.
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